

## Kenya Vaccine Support

This Decision Letter sets out the Terms of a Programme.

<b>1. Country:</b> Kenya													
<b>2. Grant Number:</b> 15-KEN-18a-X / 15-KEN-08e-Y / 15-KEN-20a-Y													
<b>3. Date of Decision Letter:</b> 14 July 2015													
<b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014													
<b>5. Programme Title:</b> NVS, Measles-Rubella Campaign													
<b>6. Vaccine type:</b> Measles-Rubella													
<b>7. Requested product presentation and formulation of vaccine:</b> Measles Rubella, 10 dose(s) per vial, LYOPHILISED													
<b>8. Programme Duration<sup>1</sup>:</b> 2015													
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>													
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;"></th> <th style="width: 30%;">2015</th> <th style="width: 30%;">Total<sup>2</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget</td> <td style="text-align: right;">US\$14,893,000</td> <td style="text-align: right;">US\$14,893,000</td> </tr> </tbody> </table>		2015	Total <sup>2</sup>	Programme Budget	US\$14,893,000	US\$14,893,000							
	2015	Total <sup>2</sup>											
Programme Budget	US\$14,893,000	US\$14,893,000											
<b>10. Vaccine Introduction Grant:</b> US\$1,257,000 payable up to six months before the introduction.													
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>3</sup></b>													
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 20%;">2015</th> </tr> </thead> <tbody> <tr> <td>Number of Measles-Rubella vaccines doses</td> <td style="text-align: right;">21,060,000</td> </tr> <tr> <td>Number of AD syringes</td> <td style="text-align: right;">20,870,300</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td style="text-align: right;">2,316,600</td> </tr> <tr> <td>Number of safety boxes</td> <td style="text-align: right;">255,075</td> </tr> <tr> <td>Annual Amounts</td> <td style="text-align: right;">US\$ 14,893,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2015	Number of Measles-Rubella vaccines doses	21,060,000	Number of AD syringes	20,870,300	Number of re-constitution syringes	2,316,600	Number of safety boxes	255,075	Annual Amounts	US\$ 14,893,000	
Type of supplies to be purchased with Gavi funds in each year	2015												
Number of Measles-Rubella vaccines doses	21,060,000												
Number of AD syringes	20,870,300												
Number of re-constitution syringes	2,316,600												
Number of safety boxes	255,075												
Annual Amounts	US\$ 14,893,000												
<b>12. Procurement agency:</b> UNICEF													
<b>13. Self-procurement:</b> Not applicable													
<b>14. Co-financing obligations:</b> Not applicable													

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

**15. Operational support for campaigns:** The support for operational costs for the campaign will be disbursed in cash through UNICEF. The Country will need to contact the local UNICEF office to arrange the utilisation of Gavi funds to support the operational costs of the campaign.

	2015
Grant amount	US\$12,332,500

**16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:**

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat
SIA technical report	Within three months of the finalisation of the campaign
Post campaign coverage survey report and actual expenditures report.	As soon as available

**17. Financial Clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
14 July 2015